Laine J, Holmberg C
Children's Hospital, University of Helsinki, Finland.
Eur J Clin Invest. 1995 Sep;25(9):670-6. doi: 10.1111/j.1365-2362.1995.tb01984.x.
CsA associated hyperkalaemia was investigated in 24 renal transplant recipients 6 months after transplantation. 51Cr-EDTA-, PAH-, lithium and sodium clearances, 24 h urinary creatinine and potassium excretions, plasma renin activity and aldosterone concentrations were measured. Transtubular potassium concentration gradient (TTKG) was calculated. An ACTH test was performed to document adrenal function. Eleven patients had hyperkalaemia. The TTKGs were low normal or reduced in both normo- and hyperkalaemic patients implying inhibition of K+ secretion. The hyperkalaemic patients received more CsA (mean dose 21.3 vs. 9.7 mg kg-1d-1, P = 0.01), and had lower lithium clearances (mean 9.9 vs. 17.0 mL min-1 1.73 m-2, P < 0.05). Adrenal function had no clear effect. Serum potassium concentration correlated with CsA dose (r = 0.773, P < 0.001) and inversely with lithium clearance (r = -0.568, P < 0.01) suggesting that CsA induced decrease in distal tubular flow rate reduced K+ excretion. Hyperkalaemia was not fully explained by renal mechanisms.
对24例肾移植受者移植后6个月时与环孢素(CsA)相关的高钾血症进行了研究。测定了51Cr - 乙二胺四乙酸(51Cr - EDTA)清除率、对氨基马尿酸(PAH)清除率、锂清除率和钠清除率、24小时尿肌酐和钾排泄量、血浆肾素活性和醛固酮浓度。计算了肾小管钾浓度梯度(TTKG)。进行促肾上腺皮质激素(ACTH)试验以记录肾上腺功能。11例患者出现高钾血症。正常血钾和高钾血症患者的TTKG均处于低正常范围或降低,这意味着钾分泌受到抑制。高钾血症患者接受的CsA更多(平均剂量21.3 vs. 9.7 mg·kg-1·d-1,P = 0.01),且锂清除率更低(平均9.9 vs. 17.0 mL·min-1·1.73 m-2,P < 0.05)。肾上腺功能无明显影响。血清钾浓度与CsA剂量相关(r = 0.773,P < 0.001),与锂清除率呈负相关(r = -0.568,P < 0.01),提示CsA导致远端肾小管流速降低,减少了钾排泄。高钾血症不能完全用肾脏机制来解释。